Correlation Between Oasmia Pharmaceutical and Viatris

Can any of the company-specific risk be diversified away by investing in both Oasmia Pharmaceutical and Viatris at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Oasmia Pharmaceutical and Viatris into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Oasmia Pharmaceutical AB and Viatris, you can compare the effects of market volatilities on Oasmia Pharmaceutical and Viatris and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Oasmia Pharmaceutical with a short position of Viatris. Check out your portfolio center. Please also check ongoing floating volatility patterns of Oasmia Pharmaceutical and Viatris.

Diversification Opportunities for Oasmia Pharmaceutical and Viatris

-0.39

Correlation Coefficient

Oasmia Pharmaceutical  Viatris

Very good diversification

The 3 months correlation between Oasmia and Viatris is -0.39. Overlapping area represents the amount of risk that can be diversified away by holding Oasmia Pharmaceutical AB and Viatris in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viatris and Oasmia Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Oasmia Pharmaceutical AB are associated (or correlated) with Viatris. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viatris has no effect on the direction of Oasmia Pharmaceutical i.e., Oasmia Pharmaceutical and Viatris go up and down completely randomly.

Pair Corralation between Oasmia Pharmaceutical and Viatris

Assuming the 90 days horizon Oasmia Pharmaceutical AB is expected to generate 16.01 times more return on investment than Viatris. However, Oasmia Pharmaceutical is 16.01 times more volatile than Viatris. It trades about 0.11 of its potential returns per unit of risk. Viatris is currently generating about 0.03 per unit of risk. If you would invest  5.00  in Oasmia Pharmaceutical AB on September 18, 2024 and sell it today you would earn a total of  1.00  from holding Oasmia Pharmaceutical AB or generate 20.0% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	5.86%
Values	Daily Returns

Oasmia Pharmaceutical AB  vs.  Viatris

Oasmia Pharmaceutical

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oasmia Pharmaceutical AB has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, Oasmia Pharmaceutical is not utilizing all of its potentials. The newest stock price disturbance, may contribute to short-term losses for the investors.

Viatris

Risk-Adjusted Performance

4 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Viatris are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Viatris may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Oasmia Pharmaceutical and Viatris

The main advantage of trading using opposite Oasmia Pharmaceutical and Viatris positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Oasmia Pharmaceutical position performs unexpectedly, Viatris can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viatris will offset losses from the drop in Viatris' long position.

The idea behind Oasmia Pharmaceutical AB and Viatris pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.